SCHEMBL2670281

SCHEMBL2670281

c1cc(Oc2cccc3c2O3)c2c(c1)O2

nearest known ligand 0.43

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AHR P35869 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29212727 0.93 AHR (0.54) AHR
SCHEMBL30525702 0.84 TSHR (0.44) AHR
SCHEMBL30786817 0.80
SCHEMBL28840933 0.80
SCHEMBL5795441 0.75 AHR (0.50) AHR
SCHEMBL15666282 0.75 AHR (0.36) AHR
SCHEMBL29712922 0.75 AHR (0.36) AHR
SCHEMBL9393907 0.72 MCHR1 (0.46)
SCHEMBL11765400 0.72 AHR (0.34) AHR
SCHEMBL30493572 0.69 AHR (0.48) AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035278-A1 Methods for synthesis of substituted tetrahydrofuran compound MILLENNIUM PHARMACEUTICALS, INC. 2002-03-21 US claimed
US-6310221-B1 PREPARING A 4-FLUOROPHENOXYMETHYL-(HYDROXY)-TETRAHYDROFURAN BY REACTING 4-FLUOROPHENOL AND AN EPOXY COMPOUND; REACTING THE EPOXY-PHENYL ETHER WITH AN ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; AND REDUCING THE LACTONE MILLENNIUM PHARMACEUTICALS, INC. 2001-10-30 US claimed
CN-1313857-A Process for the synthesis of substituted tetrahydrofuran compounds LEUKOSITE INC (US) 2001-09-19 CN claimed
EP-1102759-A1 METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND Millennium Pharmaceuticals, Inc. (US) 2001-05-30 EP claimed
WO-2000001683-A1 METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND LEUKOSITE, INC. (US) 2000-01-13 WO claimed
CN-115718406-A Photosensitive resin composition for forming resist, resin film, cured film, and semiconductor device 住友电木株式会社 2023-02-28 CN disclosed
US-20120108784-A1 HIGHLY-BRANCHED OR HYPER-BRANCHED POLYESTER AND THE PRODUCTION AND APPLICATION THEREOF BASF SE (DE) 2012-05-03 US disclosed
US-20100048813-A1 HIGHLY-BRANCHED OR HYPER-BRANCHED POLYESTER AND THE PRODUCTION AND APPLICATION THEREOF BASF SE (DE) 2010-02-25 US disclosed
CN-101583650-A Highly-branched or hyper-branched polyester and the production and application thereof BASF SE (DE) 2009-11-18 CN disclosed
EP-2091995-A1 HIGHLY-BRANCHED OR HYPER-BRANCHED POLYESTER AND THE PRODUCTION AND APPLICATION THEREOF BASF SE (DE) 2009-08-26 EP disclosed
WO-2008058886-A1 HIGHLY-BRANCHED OR HYPER-BRANCHED POLYESTER AND THE PRODUCTION AND APPLICATION THEREOF BASF SE (DE) 2008-05-22 WO disclosed
WO-2007125029-A1 HIGHLY FUNCTIONAL, HIGHLY BRANCHED OR HYPERBRANCHED POLYESTERS WITH A LOW ACID NUMBER AND PRODUCTION AND USE THEREOF BASF AKTIENGESELLSCHAFT (DE) 2007-11-08 WO disclosed
WO-2006084880-A1 METHOD FOR PRODUCING OLIGOMERISED POLYISOCYANATES AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 2006-08-17 WO disclosed
WO-2004076738-A1 LEVELLING AGENT FOR DYEING FIBRES BASF AKTIENGESELLSCHAFT (DE) 2004-09-10 WO disclosed
WO-2004054958-A1 HYDROXYALKYLATION METHOD BASF AKTIENGESELLSCHAFT (DE) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035278-A1 Methods for synthesis of substituted tetrahydrofuran compound DHFR, CYP3A4, CYP3A5 AHR 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.